Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$7.48 -0.3%	$6.61	$4.25 ▼ $9.85	$2.77B	0.41	4.52 million shs	1.88 million shs
REGN Regeneron Pharmaceuticals	$589.48 -1.5%	$550.48	$476.49 ▼ $1,211.20	$62.48B	0.33	992,485 shs	1.44 million shs
SNAP Snap	$7.19 +1.9%	$8.66	$6.99 ▼ $13.28	$12.17B	0.62	55.71 million shs	62.21 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	-10.30%	+10.42%	+67.92%	+28.43%
REGN Regeneron Pharmaceuticals	0.00%	+1.56%	+4.40%	+0.19%	-50.27%
SNAP Snap	0.00%	+0.49%	-26.18%	-12.64%	-24.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	4.18 of 5 stars	2.0	4.0	0.0	4.0	2.8	3.3	1.3
REGN Regeneron Pharmaceuticals	4.8538 of 5 stars	4.4	3.0	1.7	2.3	3.5	1.7	1.9
SNAP Snap	3.8903 of 5 stars	4.1	4.0	0.0	0.0	2.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.00	Hold	$9.00	20.30% Upside
REGN Regeneron Pharmaceuticals	2.81	Moderate Buy	$829.65	40.74% Upside
SNAP Snap	2.10	Hold	$34.16	375.46% Upside

Current Analyst Ratings Breakdown

Latest REGN, SNAP, and BHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	SNAP Snap	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	REGN Regeneron Pharmaceuticals	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2025	REGN Regeneron Pharmaceuticals	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$890.00
8/11/2025	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$940.00 ➝ $812.00
8/6/2025	SNAP Snap	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$9.00 ➝ $8.70
8/6/2025	SNAP Snap	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
8/6/2025	SNAP Snap	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
8/6/2025	SNAP Snap	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$9.00 ➝ $8.00
8/6/2025	SNAP Snap	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/6/2025	SNAP Snap	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	In-Line ➝ In-Line	$11.00 ➝ $12.00
8/6/2025	SNAP Snap	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$7.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.29	$7.71 per share	0.97	$0.40 per share	18.70
REGN Regeneron Pharmaceuticals	$14.21B	4.40	$45.70 per share	12.90	$282.48 per share	2.09
SNAP Snap	$5.36B	2.26	N/A	N/A	$1.22 per share	5.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	$0.26	28.77	1.61	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.68	14.86	15.50	1.96	31.37%	15.06%	11.77%	10/30/2025 (Estimated)
SNAP Snap	-$697.86M	-$0.32	N/A	N/A	N/A	-9.69%	-23.32%	-6.91%	11/4/2025 (Estimated)

Latest REGN, SNAP, and BHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	SNAP Snap	-$0.16	-$0.16	N/A	-$0.16	$1.34 billion	$1.34 billion
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.43	$12.89	+$4.46	$12.81	$3.30 billion	$3,675,600.00 billion
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.60%	N/A	8.87%	N/A
SNAP Snap	N/A	N/A	N/A	N/A	N/A

Latest REGN, SNAP, and BHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/18/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	8/18/2025	8/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	141.90	1.31	0.98
REGN Regeneron Pharmaceuticals	0.09	4.60	3.72
SNAP Snap	1.73	3.88	3.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
REGN Regeneron Pharmaceuticals	83.31%
SNAP Snap	47.52%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.05%
REGN Regeneron Pharmaceuticals	7.02%
SNAP Snap	22.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.33 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	105.99 million	98.55 million	Optionable
SNAP Snap	4,911	1.69 billion	1.31 billion	Optionable

REGN, SNAP, and BHC Headlines

Recent News About These Companies

Snap (NYSE:SNAP) Stock Rating Lowered by Zacks Research

August 24 at 7:28 AM | marketbeat.com

Partners Capital Investment Group LLP Acquires New Shares in Snap Inc. $SNAP

August 24 at 6:39 AM | marketbeat.com

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Snap Inc. ...

August 23 at 5:10 PM | gurufocus.com

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Snap Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SNAP

August 23 at 4:30 PM | markets.businessinsider.com

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Snap Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNAP

August 23 at 4:06 PM | globenewswire.com

SNAP INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Snap Inc. ...

August 23 at 1:10 PM | gurufocus.com

SNAP INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Snap Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 23 at 11:11 AM | mms.businesswire.com

SNAP INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Snap Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 23 at 11:03 AM | businesswire.com

Struggling Snap Considers Outside Funding for AR Glasses

August 22 at 12:20 AM | theinformation.comT

Freedom Broker Upgrades Snap Inc. (SNAP) to ‘Buy’; Reduces PT to $9

August 22 at 9:11 PM | finance.yahoo.com

Securities Fraud Investigation Into Snap Inc. (SNAP) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

August 22 at 9:11 PM | mms.businesswire.com

Securities Fraud Investigation Into Snap Inc. (SNAP) Announced â€“ Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

August 22 at 9:00 PM | businesswire.com

Securities Fraud Investigation Into Snap Inc. (SNAP) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

August 22 at 8:31 PM | mms.businesswire.com

Securities Fraud Investigation Into Snap Inc. (SNAP) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

August 22 at 8:26 PM | businesswire.com

SNAP Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Snap Inc.

August 22 at 7:38 PM | globenewswire.com

SNAP Investors with Losses in Excess of $100K Have Opportunity to Lead Snap Inc. Securities Lawsuit

August 22 at 5:59 PM | prnewswire.com

Rosen Law Firm Urges Snap Inc. (NYSE: SNAP) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

August 22 at 5:51 PM | mms.businesswire.com

SNAP SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Snap Inc. - SNAP

August 22 at 5:51 PM | mms.businesswire.com

SNAP INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Snap Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 22 at 4:00 PM | globenewswire.com

Snap Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 20, 2025 Deadline to file Lead Plaintiff Motion

August 22 at 3:29 PM | globenewswire.com

Rosen Law Firm Urges Snap Inc. (NYSE: SNAP) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

August 22 at 3:06 PM | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REGN, SNAP, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

$7.48 -0.02 (-0.25%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$7.66 +0.18 (+2.39%)

As of 08/22/2025 07:48 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Regeneron Pharmaceuticals NASDAQ:REGN

$589.48 -8.68 (-1.45%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$589.64 +0.15 (+0.03%)

As of 08/22/2025 07:50 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Snap NYSE:SNAP

$7.18 +0.14 (+1.91%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$7.20 +0.02 (+0.28%)

As of 08/22/2025 07:59 PM Eastern

Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, collection ads, dynamic ads, story ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time